Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Autolus Therapeutics Plc ADR (NQ: AUTL )

4.900 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 15, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 4.900
Bid (Size) 4.680 (1)
Ask (Size) 4.900 (2)
Prev. Close 4.900
Today's Range 4.900 - 4.900
52wk Range 1.610 - 7.450
Shares Outstanding 52,346,231
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
Autolus Therapeutics announces acceptance of Marketing Authorization Application (MAA) by the European Medicines Agency (EMA) for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia
From Autolus Therapeutics plc
Via GlobeNewswire

Performance

YTD
-28.36%
-28.36%
1 Month
-21.03%
-21.03%
3 Month
-32.04%
-32.04%
6 Month
+109.40%
+109.40%
1 Year
+166.30%
+166.30%

More News

Read More
Autolus Therapeutics Announces Changes to its Board of Directors
From Autolus Therapeutics plc
Via GlobeNewswire
Breaking Down Autolus Therapeutics: 4 Analysts Share Their Views
Via Benzinga
Autolus Therapeutics's Earnings Outlook
Via Benzinga
Analyst Expectations for Autolus Therapeutics's Future
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics PLC (NASDAQ: AUTL) Climbs to New 52-Week High
Via Investor Brand Network
Earnings Scheduled For March 14, 2024
Via Benzinga
Autolus Therapeutics announces publication in Blood Cancer Journal
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics announces publication in Nature Communications
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Announces Pricing of Underwritten Offering
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics announces publication in ACS Chemical Biology
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
From Autolus Therapeutics plc
Via GlobeNewswire
Chart Of The Day: Autolus Therapeutics - Effective Cancer Treatments
Via Talk Markets
Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
From Autolus Therapeutics plc
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
Autolus Therapeutics Announces Changes to its Board of Directors
From Autolus Therapeutics plc
Via GlobeNewswire
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023
From Autolus Therapeutics plc
Via GlobeNewswire
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)
From Autolus Therapeutics plc
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.